Ensem Therapeutics puts pan-KRAS and WRN into focus as AACR 2026 sharpens its precision oncology pitch
Read how Ensem Therapeutics is positioning ETX-929 and ETX-880 in the KRAS and MSI-H oncology races at AACR 2026.
PAQ Therapeutics initiates Phase 1 for PT0511 pan-KRAS degrader, raises $77m in Series B
PAQ Therapeutics begins Phase 1 trial for PT0511 pan-KRAS degrader and raises $77M. Find out what this means for the future of KRAS-targeted cancer therapy.